This compensated state of cardiac disease is especially interesting in terms of new therapeutic strategies acting already at early stages because it is not accompanied by gross changes of β1-AR, adenylyl cyclase, and PDE expression and activity at the whole cell level which is typical for chronic heart failure [16] (Supplementary Figures S2 and S3). This evidence concerns the gene ADRB1 and congestive heart failure.